Novavax's quarterly loss shrinks as it ramps down spending on COVID vaccines
Novavax's fourth-quarter loss narrowed on Thursday, helped by reduced selling and administrative expenses of COVID-19 ...
Novavax sees royalties, reduced expenses on COVID vaccines from Sanofi partnership
Novavax on Thursday posted a narrower fourth-quarter loss and said it expects its licensing deal with French drugmaker Sanofi ...
Novavax Inc. stock outperforms competitors on strong trading day
Shares of Novavax Inc. NVAX climbed 17.99% to $8.33 Friday, on what proved to be an all-around favorable trading session for ...
Hosted on MSN1d
Novavax Lands Wall Street 'Buy' Rating After Q4 Results, Retail Bulls Eye More Upside On Sanofi Partnership
Novavax Inc. (NVAX) shares climbed over 1% in after-hours trading Thursday as the vaccine maker's revenue outlook and ...
Novavax execs lay out 2025 game plan, talk ‘defining moment’ for business
Novavax is starting to look like a vaccine development company again. And 2025 stands to be a big year for the local biotech.
Novavax Q4 Earnings Review: Long-Term Downsizing Plan Suggests Sell Rating
Novavax, Inc. faces declining revenues and high risks despite the Sanofi deal and cost-cutting measures. Click here for my ...
Novavax Inc. stock underperforms Thursday when compared to competitors
Novavax Inc. closed 70.41% below its 52-week high of $23.86, which the company reached on June 6th.
Novavax call volume above normal and directionally bullish
Bullish option flow detected in Novavax (NVAX) with 9,851 calls trading, 2x expected, and implied vol increasing over 1 point to 83.26%. Jan-26 ...
Novavax Reports Smaller Q4 Loss, Shifts Focus From Commercializing COVID-19 Vaccine To Maximize Value
Novavax reported Q4 sales of $88.31 million, beating estimates despite a decline. The company shifts focus to partnerships ...
1 Biotech Stock to Buy in 2025, and 1 to Avoid
Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer.
Novavax reports large quarterly revenue declines, rethinks its strategic direction
Novavax (NVAX) reported a large fourth quarter sales decline Thursday — and said it no longer wants to be known simply as a ...
Novavax, Inc. (NASDAQ:NVAX) Shares Could Be 45% Below Their Intrinsic Value Estimate
Our fair value estimate is 8.2% lower than Novavax's analyst price target of US$16.43 How far off is Novavax, Inc. (NASDAQ:NVAX) from its intrinsic value? Using the most recent financial data, we'll ...